Lilly halts trial of antibody drug Trump touted as cure over safety concern

By Michael Erman and Carl O'Donnell (Reuters) - Eli Lilly and Co said on Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment similar to one taken by U.S.

President Donald Trump has been paused because of a safety concern. Trump touted the Lilly drug, along with the antibody treatment from Regeneron Pharmaceuticals Inc that he received for his COVID-19, as tantamount to a cure in a video he posted last week. The announcement comes one day after Johnson & Johnson said it was forced to pause.....

This article is no longer available in our repository.

There could be multiple reasons for this.